bamadutide
- Generic Name
- bamadutide
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
- Conditions
- Non-alcoholic SteatohepatitisType 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Registration Number
- NCT03437720
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 60
- Registration Number
- NCT03414736
- Locations
- ๐บ๐ธ
Investigational Site Number 8400003, Knoxville, Tennessee, United States
๐บ๐ธInvestigational Site Number 8400002, Saint Paul, Minnesota, United States
๐บ๐ธInvestigational Site Number 8400001, Austin, Texas, United States
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 24
- Registration Number
- NCT03376802
- Locations
- ๐บ๐ธ
Investigational Site Number 8400001, Orlando, Florida, United States
๐บ๐ธInvestigational Site Number 8400002, Baton Rouge, Louisiana, United States
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer)Drug: [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13
- Registration Number
- NCT03350191
- Locations
- ๐ธ๐ช
Investigational Site Number 7520001, Uppsala, Sweden
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-11-25
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 296
- Registration Number
- NCT02973321
- Locations
- ๐ท๐บ
Investigational Site Number 6430003, Saratov, Russian Federation
๐ท๐บInvestigational Site Number 6430001, St-Petersburg, Russian Federation
๐ท๐บInvestigational Site Number 6430005, Voronezh, Russian Federation
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-04-08
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 76
- Registration Number
- NCT02411825
- Locations
- ๐ฉ๐ช
Investigational Site Number 276001, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.